Forte Biosciences Inc (FBRX)

Nov 25, 2024, 9:00 AM EST - 7 weeks ago

Forte Biosciences to Host R&D Day December 3, 2024

Nov 20, 2024, 9:00 AM EST - 2 months ago

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Nov 14, 2024, 4:01 PM EST - 2 months ago

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Aug 14, 2024, 4:01 PM EDT - 5 months ago

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

May 17, 2024, 4:05 PM EDT - 8 months ago

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

May 13, 2024, 4:05 PM EDT - 8 months ago

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

Mar 18, 2024, 4:05 PM EDT - 10 months ago

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

Dec 1, 2023, 4:01 PM EST - 1 year ago

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Nov 13, 2023, 4:01 PM EST - 1 year ago

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

Sep 14, 2023, 10:50 AM EDT - 1 year ago

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

Sep 6, 2023, 3:15 PM EDT - 1 year ago

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's Boardroom

Aug 25, 2023, 8:00 AM EDT - 1 year ago

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

Aug 14, 2023, 4:01 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update

Aug 1, 2023, 4:01 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

May 15, 2023, 4:01 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

Mar 31, 2023, 4:05 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Jan 12, 2023, 4:05 PM EST - 2 years ago

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 2 years ago

Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 2 years ago

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Aug 17, 2022, 8:00 AM EDT - 2 years ago

Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise

Aug 15, 2022, 4:05 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Jun 7, 2022, 9:00 AM EDT - 2 years ago

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

May 16, 2022, 9:00 AM EDT - 2 years ago

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

Sep 6, 2021, 12:42 PM EDT - 3 years ago

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Sep 3, 2021, 2:31 PM EDT - 3 years ago

Why Forte Biosciences Stock Is Down Over 80% Today

Sep 3, 2021, 12:19 PM EDT - 3 years ago

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

Sep 3, 2021, 7:21 AM EDT - 3 years ago

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

Sep 2, 2021, 5:47 PM EDT - 3 years ago

Forte Biosciences Just Plummeted 80%: Here's Why

Sep 2, 2021, 4:05 PM EDT - 3 years ago

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

Aug 16, 2021, 4:05 PM EDT - 3 years ago

Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

May 11, 2021, 7:24 AM EDT - 4 years ago

Forte Biosciences, Inc. (FBRX) CEO Paul Wagner on Q1 2021 Results - Earnings Call Transcript

May 10, 2021, 4:05 PM EDT - 4 years ago

Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

May 3, 2021, 4:30 PM EDT - 4 years ago

Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

Apr 9, 2021, 6:07 AM EDT - 4 years ago

Forte Biosciences: Microbiome Therapeutics For Skin Disease

Apr 8, 2021, 6:59 PM EDT - 4 years ago

Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market

Mar 29, 2021, 12:10 PM EDT - 4 years ago

Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

AMGN AXP CAT IMOM JPM UNH VRA

Mar 24, 2021, 8:00 AM EDT - 4 years ago

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

Mar 17, 2021, 4:05 PM EDT - 4 years ago

Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update

Feb 23, 2021, 4:01 PM EST - 4 years ago

Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th

Feb 18, 2021, 4:01 PM EST - 4 years ago

Forte Biosciences, Inc. to Present at the Cowen Annual Health Care Conference on March 1st

Dec 18, 2020, 5:36 PM EST - 4 years ago

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Nov 24, 2020, 4:05 PM EST - 4 years ago

Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd

Nov 10, 2020, 4:05 PM EST - 4 years ago

Forte Biosciences, Inc. to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th

Nov 9, 2020, 4:05 PM EST - 4 years ago

Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update

Nov 2, 2020, 4:30 PM EST - 4 years ago

Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9

Nov 2, 2020, 4:05 PM EST - 4 years ago

Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 29, 2020, 8:00 AM EDT - 4 years ago

Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock

Oct 28, 2020, 4:09 PM EDT - 4 years ago

Forte Biosciences Announces Proposed Public Offering of Common Stock